Clinical Trials Logo

Filter by:
NCT ID: NCT05643833 Completed - Cancer of Liver Clinical Trials

Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular Carcinoma

Start date: January 1, 2021
Phase:
Study type: Observational

This is a large-scale study in China to provide evidence and insights in the role of gender in LT for HCC by analyzing the data of 3769 recipients with HCC registered in the China Liver Transplant Registry.

NCT ID: NCT05643066 Completed - Clinical trials for Postoperative Recovery

Esketamine-propofol Versus Propofol for Flexible Bronchoscopy

Start date: December 7, 2022
Phase: Phase 4
Study type: Interventional

Bronchoscopy is a promising technology for lung and bronchus disease detection and therapy. However, this procedure is associated with a relatively high risk of hypoxemia, coughing, wheezing, and dyspnea. Despite the fact that propofol is the most commonly used agent in procedure sedation, the narrow therapeutic index remains challenging. Esketamine is the s-enantiomer of ketamine with potent analgesic and sedative properties. This study aims to test the hypothesis that adding subanesthetic esketamine to propofol is non-inferior to propofol alone for bronchoscopy on the recovery profile and discharge from the hospital.

NCT ID: NCT05642624 Completed - Fungal Infection Clinical Trials

The PK/PD of Deoxycholic Acid Amphotericin B in Invasive Fungal Infection Patients With Sepsis/Septic Shock

Start date: February 28, 2019
Phase:
Study type: Observational

To explore the PK/PD of deoxycholic amphotericin B in invasive fungal infection patients with sepsis/septic shock;To compare the PK/PD of deoxycholic amphotericin B in invasive fungal infection patients with sepsis and septic shock.

NCT ID: NCT05642585 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

A Study of Single-dose MY008211A in Healthy Adults

Start date: May 27, 2022
Phase: Phase 1
Study type: Interventional

The trial is the first human trial. The safety, tolerability, PK and PD of MY008211A Tablets will be evaluated in healthy subjects.

NCT ID: NCT05642403 Completed - Clinical trials for Respiratory Syncytial Virus Infections

A Study of XW001 in Healthy Adult Subjects

Start date: January 3, 2021
Phase: Phase 1
Study type: Interventional

This is the first-in-human, single-center, randomized, double-blinded, placebocontrolled, single-dose and multiple-dose escalation Phase Ia study

NCT ID: NCT05642247 Completed - Crohn Disease Clinical Trials

Quantify the Value of Transmural Inflammation in the Treatment of Crohn's Disease With Ustekinumab:an Analysis Based on Imaging Science

Start date: July 1, 2022
Phase:
Study type: Observational

Crohn's disease(CD),a type of inflammatory bowel disease(IBD), is a chronic intestinal recurrent inflammatory disease involving the entire digestive tract. And Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, is a newly targeted drug approved for the treatment of Crohn's disease in recent years.Based on the high-throughput imaging characteristic analysis technique, this study quantitatively analyzed the transmural inflammation of Crohn's disease, and discussed its prognostic value in the treatment of Ustekinumab, and further analyzed the increment of its relative clinical index.

NCT ID: NCT05642078 Completed - Clinical trials for Prevention of Influenza

Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

Start date: February 18, 2023
Phase: Phase 3
Study type: Interventional

A randomized, blind, positive vaccine control trial was designed.A total of 2550 subjects aged 6-35 months were randomly assigned to the low dose (0.25ml/ dose) group, the high dose (0.5ml/ dose) group and the control group in a ratio of 1:1:1. They were inoculated with 2 doses of quadrivalent influenza virus split vaccine (experimental vaccine or control vaccine) at 0 and 28 days of immunization program to observe the Immunogenicity and safety.

NCT ID: NCT05641558 Completed - Dermatitis, Atopic Clinical Trials

Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis

Start date: October 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of the study was to evaluate the safety and tolerability of 611 in chinese adults with moderate to severe atopic dermatitis.

NCT ID: NCT05640804 Completed - Clinical trials for Leukemia, Myelogenous, Chronic

A Bioequivalence Study of Dasatinib Tablet

Start date: September 9, 2018
Phase: Phase 1
Study type: Interventional

This is a clinical study to evaluate the bioequivalence of dasatinib tablet produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Sprycel® produced by Bristol Myers Squibb after single dose in healthy subjects, so as to provide reference for clinical evaluation and clinical medication; to observe the safety of the dasatinib tablet and the reference drug Sprycel® in healthy subjects under fasting and fed states.

NCT ID: NCT05640570 Completed - Common Cold Clinical Trials

The Preventive Effectiveness of the Individualized Jade Wind-Barrier Herbal Tea Bag on the Common Cold in Elderly With Qi-deficiency Constitution (CCJWBT): A Pragmatic Randomized Controlled Trial

CCJWBT
Start date: February 21, 2022
Phase: Phase 2
Study type: Interventional

Objectives Based on the individualized Jade Wind-Barrier Herbal Tea Bag intake after randomization, to evaluate the relationship of the individualized Jade Wind-Barrier Herbal Tea Bag intake and the improvement of Qi-deficiency Constitution on the common cold-associated outcomes. Specific Aims 1: To compare the incidence and recurrence of the common cold by the individualized Jade Wind-Barrier Herbal Tea Bag intake strategies (intake 3-month individualized Jade Wind-Barrier Herbal Tea Bag vs. no intake throughout the same trial period) in the HK Qi-deficiency Constitution elderly. Specific Aims 2: To determine the immunological index(es) and function changes by the intake strategies (intake 3-month individualized Jade Wind-Barrier Herbal Tea Bag vs. no intake throughout the same trial period) on the common cold among HK Qi-deficiency Constitution elderly. Specific Aims 3: To assess the change in the reductive ratio of the total scores of the Clinical Features of the Qi-deficiency Constitution Questionnaire by the individualized Jade Wind-Barrier Herbal Tea Bag intake strategies (intake 3-month individualized Jade Wind-Barrier Herbal Tea Bag vs. no intake throughout the same trial period) in the HK Qi-deficiency Constitution elderly.